Clinical Care Implementation of Guidelines for Genomic Testing

Naveen Pereira MD, FACC, FAHA, FRCPE Professor of Medicine, Mayo Clinic

Disclosures

Funding NHLBI Mayo Clinic



Clinicians follow professional society guidelines



ACC/ AHA Guidelines – Class of Recommendation

- Benefits versus Risk
- Recommendations
 - Class 1 Is recommended
 - Class 2a Is reasonable
 - Class 2b May/might be reasonable
 - Class 3a Is not recommended
 - Class 3b Potentially harmful or causes harm



ACC/ AHA Guidelines – Level of Evidence

► RCTs

- Meta-analyses of high quality RCTs
- Well-designed, well-executed nonrandomized studies, observational, or registry studies
- Meta-analyses of such studies




Clinicians follow professional society guidelines

Pharmacogenomics as an example



Background




Nature Reviews Cardiology 2009



CYP2C19 LOF carriers

- 1 in 3 individuals may be LOF carriers
- AUC₀₋₂₄ is up to 46% and C_{max} up to 40% lower that of non-carriers for the active metabolite



J Thrombosis and Haemostasis 2008; JAMA 2011



CYP2C19 LOF carriers vs Non-carriers Risk of CV death, MI, or stroke

	No. No. indiv				
	1 or 2	None	Hazard ratio (95% CI)	Increased Risk in Non-carriers	Increased Risk in Carriers
Clarity-TIMI 28	8/77	10/150	1.56 (0.61-3.94)		
EXCELSIOR	5/243	7/554	1.63 (0.52-5.14)		
TRITON-TIMI 38	46/395	83/1064	1.53 (1.07-2.19)		
AFIJI	15/73	11/186	5.38 (2.32-12.47)		
FAST-MI	63/635	193/1573	0.79 (0.59-1.06)	_	
RECLOSE	15/247	14/525	2.32 (1.12-4.81)	_	
ISAR	55/680	119/1805	1.23 (0.89-1.70)		
CLEAR- PLATELETS	6/68	4/160	3.95 (1.11-14.02)		
Intermountain	68/344	141/906	1.29 (0.97-1.72)		
Totals	281/2762	582/6923	1.57 (1.13-2.16)		
JAMA 2010				0.1 0.2 0.5 <i>P</i> =.006 Hazard Ra	1 2 5 10 tio (95% CI)

Clopidogrel: Black-box warning

PLAVIX[®] (clopidogrel bisulfate) tablets Initial U.S. Approval: 1997

> WARNING: DIMINISHED EFFECTIVENESS IN POOR METABOLIZERS

See full prescribing information for complete boxed warning.

· Effectiveness of Plavix depends on activation to an active



• ALTERNATIVE THERAPY

 Lests are available to identify a patient's CYP2C19 genotype and can be used as an aid in determining therapeutic strategy. (12.5)

 Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers. (2.3, 5.1)

March 12, 2010



In addition, there are other genetic polymorphisms such as ABCB1 that may also contribute to variation in the response of individual patients to clopidogrel.

Information about the predictive value of pharmacogenomic testing is very limited, but is the focus of multiple ongoing studies. The design of such studies in terms of specific tests and patient populations (eg, acute care versus chronic care settings) will have major implications for the role of testing. A related issue is whether the risk from a given individual's genomic profile changes over time, depending on the specific clinical scenario (eg, ACS versus stable angina pectoris, PCI versus medical therapy, small vessel versus large artery, atherosclerotic ischemic stroke, or carotid stenting versus medical therapy), is relevant. This question has yet to be resolved.

4. The answer to the specific question of the role of genotyping in everyday practice remains unknown at the present time. Although the boxed warning does not mandate testing, proponents would argue that there are common genetic wide variety of situations. New agents such as prasugrel and ticagrelor, which are not affected by CYP2C19 genetic variants, have been found to be more effective than standarddose clopidogrel. This relates to the PK characteristics of these newer agents. In very high-risk clinical circumstances (eg. prior stent thrombosis) such agents may be considered alternatives to standard ACCF/AHA and AHA Stroke Council Guideline therapy. This is particularly important in any patient suspected of treatment failure to standard-dose clopidogrel. Other treatment strategies are also being tested, including increased clopidogrel dosing or the addition of a third drug such as cilostazol to aspirin and clopidogrel. In the setting of stroke or transient ischemic neurologic symptoms, the combination of aspirin and extended release dipyridamole and aspirin monotherapy are alternatives recommended by the AHA Stroke Council guidelines for secondary prevention of stroke.66

6.2. Recommendations for Practice

The evidence base is insufficient to recommend either routine genetic or platelet function testing at the present time. There is no information that routine testing improves outcome in large subgroups of patients.

> other variants including the gain-of-function CYP2C19*17 variant (hyper-rapid or ultrarapid metabolizers). As part of this argument, opponents note that the predictive performance of CYP2C19 variant is low, ranging from 12% to 20%, and raise the question of what to do when variant genotype information is identified in patients with no clinical events. Finally, they would note that there are no point-ofcare genotyping tests, which severely limits the usefulness of these data in the acute care setting. Currently, there are studies underway or in the planning stages that will address these issues to varying degrees. Despite the gaps in current knowledge, both clinicians and patients need to be aware of genetic polymorphisms that may modulate clopidogrel responsiveness and cause MACE. It is important to emphasize again that in the most recent labeling for clopidogrel, the FDA only informs physicians and patients that genetic testing is available; it neither mandates, requires, nor recommends genetic testing, thereby allowing for flexibility in clinical decisions.

5. Given the concerns about the mortality and morbidity that may be attributable to an inadequate response to antiplatelet therapy, there are a number of alternative approaches to standard guideline-based care with clopidogrel. New agents and new strategies have been used clinically and tested in a the importance of CYP2C19*2 versus *3 or *4 for a specific patient), and the frequency of genetic variability differs among ethnic groups. This has particular relevance related to the frequency of homozygotes, which occurs in approximately 2% of the population, versus heterozygotes, which occurs in approximately 30% of the population, both of whom may have increased risk.

4. Information regarding the predictive value of pharmacogenomic testing is very limited at this time; resolution of this issue is the focus of multiple ongoing studies. The selection of the specific test, as well as the issue of reimbursement, are both important additional considerations.

. The evidence base is insufficient to recommend either routine genetic or platelet function testing at the present time. There is no information that routine testing improves outcome in large subgroups of patients. In addition, the emnca course or me majority or patients treated winn clopidogrel without either genetic testing or functional testing is excellent. Clinical judgment is required to assess clinical risk and variability in patients considered to be at increased risk. Genetic testing to determine if a patient is predisposed to poor clopidogrel metabolism ("poor metabolizers") may be considered before starting clopidogrel

Circulation 2010



Genotype-based Clinical Trials ≻Allele frequency ≻Number of homozygotes

- Effect size
- Trial design complexity and sample size
- Ethics


Regulations and FDA

Circ Cardiovas Interv 2019



Primary Endpoint


Composite of CV death, MI, stroke, stent thrombosis, severe recurrent ischemia



JAMA 2020



CYP2C19 Genetic Testing – Meta-Analysis



JACC Intv. 2021

2020 MFMER | 3948880-14

Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis

Mattia Galli, Stefano Benenati, Davide Capodanno, Francesco Franchi, Fabiana Rollini, Domenico D'Amario, Italo Porto, Dominick J Angiolillo

- ► ↓ Major Cardiovascular Events (RR 0.78, 95% CI 0.63-0.95, p=0.015)
- Cardiovascular Death (RR 0.77, 95% CI 0.50-1.00, p=0.049)
- ▶ ↓ MI (RR 0.76, 95% CI 0.60-0.96, p=0.021)
- ► ↓ Stent Thrombosis (RR 0.64, 95% CI 0.46-0.89, p=0.011)
- ► ↓ Stroke (RR 0.66, 95% CI 0.48-0.91, p=0.010)
- ▶ ↓ Minor Bleeding (RR 0.78, 95% CI 0.67-0.92, p=0.0030)

Funding None.



Lancet 2021

AHA SCIENTIFIC STATEMENT

CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association

Naveen L. Pereira, MD, FAHA, Chair; Sharon Cresci, MD, FAHA, Vice Chair; Dominick J. Angiolillo, MD, PhD; Wayne Batchelor, MD, MHS; Quinn Capers IV, MD; Larisa H. Cavallari, PharmD; Dana Leifer, MD, FAHA; Jasmine A. Luzum, PharmD, PhD, FAHA; Dan M. Roden, MD, FAHA; Konstantinos Stellos, MD, FAHA; Stephanie L. Turrise, PhD, RN, FAHA; Sony Tuteja, PharmD, MS, FAHA; on behalf of the American Heart Association Professional/Public Education and Publications Committee of the Council on Genomic and Precision Medicine; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease; and Stroke Council

Circulation 2024



Clinicians follow professional society guidelines

Clopidogrel - CYP2C19 yet to be addressed




Challenges to Clinical Implementation

- Evidence of clinical utility
- Objective practice guidelines
- Availability of rapid turn-around genotyping performed in a CLIAapproved environment
- Incorporation of genotype data in an electronic medical record
- ► EHR "alerts" at the point of care
- Education of clinicians patients
- User friendly decision support software/tools
- Insurance coverage and cost
- Clinician and patient perceptions



Preemptive genetic testing Mayo-Baylor RIGHT 10K Study




Number of Genes	Number of Subjects	% of Subjects
0	59	0.6%
1	465	4.6%
2	1636	16.2%
3	2893	28.7%
4	2869	28.5%
5	1521	15.1%
6	514	5.1%
7	111	1.1%
8	9	0.1%

Genetics in Medicine 2022



2020 MFMER | 3948880-19

Operational Model to Implement Genetic Testing *at* **Point of Care**



Genetic Test Reporting – Decreasing Complexity

BestPractice	Advisory - Cdstesting	g,Adt				
High Pı	riority (1)					1
	RMACOGENOMI ential for toxicity.	CS ALERT: This patient	is a CYP2D6 Ultra Rapid	metabolizer. Av	void codeine due to	2
Rei	move the following	g orders?				
	Remove	Keep ca	butalbital-aspirin-caff-co psule (FIORINAL WITH CO apsule, oral, Every 4 hours PRN	DDEINE)		I
Ger	nomic Indicators a					
For	more information g	jo to AskMayoExpert (co	deine) 🖳			
Ack	knowledge Reason					
Be	nefit outweighs risk	Patient previously tolerated	Therapeutically appropriate	Will cancel order	Other reason	
					<u>✓ A</u>	ccept







Department of Cardiovascular Medicine Dilated Cardiomyopathy (DCM) Genetic Testing

Only 13% of eligible patients undergo genetic testing



DCM Genetic Testing Process

Genetic testing and clinical workflows $\geq @$ point of clinical care Pre-emptive identification of eligible patients and opt-out option >Use existing clinical resources >Automate genetic counseling Transparency regarding cost >Virtual engagement to provide results



DCM Genetic Testing: Mayo Clinic Experience

- Genetic counseling pre-INT vs post-INT (14.8% vs 33.5%, OR 2.9, P<.0001)</p>
- Genetic testing pre-INT vs post-INT (13% vs 27.3%, OR 2.5, P=.001)
- Likely pathogenic or pathogenic DCM related genetic variants detection increased from 2 pre to 6 post-intervention



Take home points

- Clinicians follow professional society guidelines
- Guidelines are primarily driven by results of clinical trials but maybe biased when totality of data should be assessed
- Developing and conducting genotype-based clinical trials is complex
- Availability of genetic testing and results at the point of care is essential
- Institutional support and multidisciplinary teams involving clinicians, the laboratory, informatics, and IT resources are required
- Incorporating genetic testing within existing workflows including engaging clinicians, patients with insurance approvals/payments increases its adoption





Questions? pereira.naveen@mayo.edu @nl_pereira

